risks of glp 1 inhibitors Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia GLP-1 Receptor Agonists and vision

Currently approved GLP-1 receptor agonists in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Bydureon BCise)

The role of DXA bone density scans in the diagnosis and treatment of osteoporosis

Trulicity improves patient convenience with its user-friendly autoinjector device (like an EpiPen), the first available for this class of drugs

The Lancet Obstetrics, Gynaecology & Womens Health, 2(2), e118e128

Overall, we found that physicians are doubtful about the potential for GLP-1s to drive long-term weight loss, lower costs, or make any real impact on the obesity epidemic